RxSight (RXST) Cash from Financing Activities (2020 - 2026)
RxSight's (RXST) quarterly Cash from Financing Activities came in at -$336000.0 in Q1 2026, up 54.29% YoY from -$217777.8 in Q1 2025, and down 131.61% on a QoQ basis from $1.1 million in Q4 2025.
RxSight (RXST) Cash from Financing Activities (2020 - 2026) Analysis & Trends
RxSight (RXST) has 7 years of Cash from Financing Activities data on file, last reported at -$336000.0 in Q1 2026.
- Quarterly Cash from Financing Activities rose 54.29% year-over-year to -$336000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.3 million (down 98.03% YoY) and the FY2025 annual result came in at $1.9 million, down 98.49% from the prior year.
- Cash from Financing Activities retreated to -$336000.0 in Q1 2026, from $1.1 million in the prior quarter.
- In the past five years, Cash from Financing Activities ranged from a high of $111.5 million in Q2 2024 to a low of -$8.2 million in Q3 2023.
- A 5-year average of $11.3 million and a median of $891000.0 in 2023 frame the typical range for Cash from Financing Activities.
- The widest YoY moves for Cash from Financing Activities: up 66737.76% in 2023, down 1709.67% in 2023.
- Tracing RXST's Cash from Financing Activities over 5 years: stood at $6.3 million in 2022, then tumbled by 43.52% to $3.6 million in 2023, then slipped by 16.45% to $3.0 million in 2024, then sank by 64.28% to $1.1 million in 2025, then slumped by 131.61% to -$336000.0 in 2026.
- The last three Cash from Financing Activities figures came in at -$336000.0 (Q1 2026), $1.1 million (Q4 2025), and -$530000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 198.70 Bn | 193.10 Bn | 7.27 Bn | -3.52 Bn |
| 2 | Stryker | 125.85 Bn | 122.37 Bn | 4.50 Bn | -95.00 Mn |
| 3 | Medtronic | 118.44 Bn | 109.22 Bn | 6.41 Bn | -888.00 Mn |
| 4 | Boston Scientific | 72.64 Bn | 72.10 Bn | 3.85 Bn | -410.00 Mn |
| 5 | Edwards Lifesciences | 51.94 Bn | 47.69 Bn | 1.35 Bn | -300,000.00 |
| 6 | Dexcom | 34.48 Bn | 32.53 Bn | 830.00 Mn | -607.30 Mn |
| 7 | GE HealthCare Technologies | 33.60 Bn | 31.49 Bn | 2.18 Bn | -236.00 Mn |
| 8 | Koninklijke Philips | 26.30 Bn | 22.98 Bn | 4.55 Bn | -1.34 Bn |
| 9 | Steris | 23.00 Bn | 22.52 Bn | 684.20 Mn | -213.50 Mn |
| 10 | RxSight | 250.81 Mn | -153.43 Mn | - | 662,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 662,000.00 |
| Jun 30, 2026 | 662,000.00 |
| Mar 31, 2026 | -336,000.00 |
| Mar 31, 2026 | -336,000.00 |
| Dec 31, 2025 | 1.06 Mn |
| Dec 31, 2025 | 1.06 Mn |
| Sep 30, 2025 | -530,000.00 |
| Sep 30, 2025 | -530,000.00 |
| Jun 30, 2025 | 2.07 Mn |
| Jun 30, 2025 | 2.07 Mn |
| Mar 31, 2025 | -735,000.00 |
| Mar 31, 2025 | -735,000.00 |
| Dec 31, 2024 | 2.98 Mn |
| Dec 31, 2024 | 2.98 Mn |
| Sep 30, 2024 | 878,000.00 |
| Sep 30, 2024 | 878,000.00 |
| Jun 30, 2024 | 111.47 Mn |
| Jun 30, 2024 | 111.47 Mn |
| Mar 31, 2024 | 7.99 Mn |
| Mar 31, 2024 | 7.99 Mn |